Cargando…

Clozapine haematological monitoring for neutropenia: a global perspective

AIMS: Clozapine is licensed for treatment-resistant psychosis and remains underutilised. This may berelated to the stringent haematological monitoring requirements that are mandatory in most countries. We aimed to compare guidelines internationally and develop a novel Stringency Index. We hypothesis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oloyede, Ebenezer, Blackman, Graham, Whiskey, Eromona, Bachmann, Christian, Dzahini, Olubanke, Shergill, Sukhi, Taylor, David, McGuire, Philip, MacCabe, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714212/ https://www.ncbi.nlm.nih.gov/pubmed/36426600 http://dx.doi.org/10.1017/S204579602200066X

Ejemplares similares

The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
por: Taylor, David, et al.
Publicado: (2022)

Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Management of clozapine treatment during the COVID-19 pandemic
por: Gee, Siobhan, et al.
Publicado: (2020)

Vortioxetine as adjunctive therapy in the treatment of schizophrenia
por: Redaelli, Sofia, et al.
Publicado: (2022)

A retrospective case notes review of the effectiveness and tolerability of metoclopramide in the treatment of clozapine-induced hypersalivation (CIH)
por: Livermore, Cecilia, et al.
Publicado: (2022)

Real-world effectiveness of admissions to a tertiary treatment-resistant psychosis service: 2-year mirror-image study
por: Casetta, Cecilia, et al.
Publicado: (2020)

Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation—Is It Feasible to Develop Evidence-Based Guidelines?
por: Blackman, Graham, et al.
Publicado: (2021)

Benign ethnic neutropenia: an analysis of prevalence, timing and identification accuracy in two large inner-city NHS hospitals
por: Oloyede, Ebenezer, et al.
Publicado: (2021)

What are the barriers and facilitators of clozapine use in early psychosis? A survey of UK early intervention clinicians
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Closure beyond clozapine: successfully averting rebound symptoms in a patient with schizoaffective disorder and agranulocytosis
por: Green, Alastair, et al.
Publicado: (2019)

Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review
por: Oloyede, Ebenezer, et al.
Publicado: (2022)

Successful clozapine rechallenge following recurrent clozapine-associated pancreatitis: a case report
por: Rodriguez, Victoria, et al.
Publicado: (2020)

Clozapine for treatment resistance in early psychosis: a survey of UK clinicians’ training, knowledge and confidence
por: Oloyede, Ebenezer, et al.
Publicado: (2022)

Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations
por: Krivoy, Amir, et al.
Publicado: (2021)

Clozapine discontinuation withdrawal symptoms in schizophrenia
por: Blackman, Graham, et al.
Publicado: (2021)

Change in plasma concentration of clozapine and norclozapine following a switch of oral formulation
por: Keshavarzi, Farinaz, et al.
Publicado: (2020)

Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland
por: Ingimarsson, Oddur, et al.
Publicado: (2016)

Clozapine Response in Schizophrenia and Hematological Changes
por: Blackman, Graham, et al.
Publicado: (2021)

Resolution without discontinuation: heart failure during clozapine treatment
por: Whiskey, Eromona, et al.
Publicado: (2020)

Using a fingerstick test for haematological monitoring in patients treated with clozapine
por: Atkins, Matthew, et al.
Publicado: (2021)

Clozapine-induced agranulocytosis
por: Mijovic, Aleksandar, et al.
Publicado: (2020)

Possible pharmacogenetic factors in clozapine treatment failure: a case report
por: Whiskey, Eromona, et al.
Publicado: (2021)

Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy
por: Segev, Aviv, et al.
Publicado: (2021)

Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy – ERRATUM
por: Segev, Aviv, et al.
Publicado: (2021)

41. RECONSIDERING THE EVIDENCE FOR CLOZAPINE FOR TREATMENT REFRACTORY SCHIZOPHRENIA
por: MacCabe, James
Publicado: (2018)

The side effect profile of Clozapine in real world data of three large mental health hospitals
por: Iqbal, Ehtesham, et al.
Publicado: (2020)

Successful clozapine re-challenge in a patient with three previous episodes of clozapine-associated blood dyscrasia
por: Foster, Jessica, et al.
Publicado: (2017)

Inflammatory response to clozapine in the absence of myocarditis: case report
por: Davey, Patrick, et al.
Publicado: (2016)

T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Egerton, Alice, et al.
Publicado: (2020)

When the drugs don’t work: treatment-resistant schizophrenia, serotonin and serendipity
por: Lowe, Penelope, et al.
Publicado: (2017)

41.3 COULD CLOZAPINE REDUCE VIOLENT OFFENDING?
por: Bhavsar, Vishal, et al.
Publicado: (2018)

Late-onset neutropenia due to clozapine
por: Tatar, Zeynep Baran, et al.
Publicado: (2015)

Clozapine-Induced Febrile Neutropenia and Cellulitis
por: YAYLACI, Selcuk, et al.
Publicado: (2016)

M212. A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL VARIABLES ASSOCIATED WITH RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Griffiths, Kira, et al.
Publicado: (2020)

Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report
por: Sanchez, Asiel Yair Adan, et al.
Publicado: (2016)

Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis
por: Verbelen, M, et al.
Publicado: (2015)

Biological Predictors of Clozapine Response: A Systematic Review
por: Samanaite, Ruta, et al.
Publicado: (2018)

Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report — ADDENDUM
por: Sanchez, Asiel Yair Adan, et al.
Publicado: (2019)

Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia
por: Legge, S E, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ing3q92okk5d80f9mtoeeh7j5f